Batoclimab

Batoclimab (RVT-1401) is a fully humanized IgG1 monoclonal antibody targeting FcRn. Batoclimab has high affinity for the IgG-binding site on FcRn. By competitively binding to the IgG binding site on FcRn, Batoclimab blocks FcRn-mediated recycling of IgG, resulting in enhanced degradation and subsequent reductions in IgG levels. Batoclimab can be used in the research of autoimmune diseases such as myasthenia gravis and thyroid eye disease[1][2].

Product Specifications

CAS Number

[2187430-05-1]

Product Name Alternative

RVT-1401; HBM9161; IMVT-1401

UNSPSC

12352203

Target

Fc Receptor (FcR)

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/batoclimab.html

Purity

99.89

Solubility

H2O

Smiles

[Batoclimab]

Molecular Weight

(143.43 kDa)

References & Citations

[1]Yan C, et, al. Therapeutic Effects of Batoclimab in Chinese Patients with Generalized Myasthenia Gravis: A Double-Blinded, Randomized, Placebo-Controlled Phase II Study. Neurol Ther. 2022 Apr 12. |[2]Kahaly GJ, et al. Proof-of-concept and Randomized, Placebo-controlled Trials of an FcRn Inhibitor, Batoclimab, for Thyroid Eye Disease. J Clin Endocrinol Metab. 2023 Nov 17;108 (12) :3122-3134.